Introduction: Currently, embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) can be induced to differentiate at the cellular level but not to form mature tissues or organs suitable for transplantation. ESCs/iPSCs form immature teratomas after injection into immunodeficient mice. In humans, immature teratomas often transform into fully differentiated mature teratomas after administration of anticancer agents.
Methods: We first investigated the ability of cisplatin to induce changes in mouse ESCs/iPSCs in vitro. Next, we designed experiments to analyze ESC/iPSC-derived immature teratoma tissue in vivo after treatment of cisplatin. Groups of six mice carrying ESC- or iPSC-derived teratomas were given either low or high dose intraperitoneal injection of cisplatin, while the control group received saline for 4 weeks.
Results: Treatment of ESC/iPSC cultures with cisplatin for 3 days caused a dose-related decrease in cell numbers without inducing any morphological changes to the cells. ESC/iPSC-derived teratomas showed lower growth rates with a significantly higher mature components ratio in a concentration dependent manner after cisplatin treatment (P < 0.05); however, immunohistochemical analyses demonstrated a significantly reduced PCNA labelling index and an increase in an apoptosis marker on immature neural components (P < 0.05) along with emergence of h-Caldesmon+ mature smooth muscle cells in treated mice. Moreover, newly differentiated components not found in the control group, such as mature adipose tissue, cartilage, and pancreas, as well as striated muscle, salivary glands, gastric mucosa with fundic glands, and hair follicles emerged. The identities of these components were confirmed by immunostaining for specific markers.
Conclusions: Cisplatin has the ability to reduce immature components in ESC/iPSC-derived teratomas, presumably through apoptosis, and also to induce them to differentiate.
Keywords: ALP, alkaline phosphatase; ATP4B, ATPase H+/K+ transporting beta subunit; CR, chemotherapeutic retroconversion; Cisplatin; DMEM, Dulbecco's modified Eagle's medium; Differentiation; ESC, embryonic stem cell; Embryonic stem cells; FCS, fetal calf serum; HE, hematoxylin and eosin; Immature teratoma; Induced pluripotent stem cells; KSR, knockout serum replacement; LIF, leukemia inhibitory factor; MEF, mouse embryonic fibroblast; PBS, phosphate buffered saline; PCNA, proliferating cell nuclear antigen; RAG, recombination activating gene; RLU, relative light units; RT, room temperature; iPSC, induced pluripotent stem cell; ssDNA, single stranded DNA; α-SMA, α-smooth muscle actin.
© 2021 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.